237 related articles for article (PubMed ID: 17535433)
21. Quantitative RT-PCR assays for the determination of urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 mRNA in primary tumor tissue of breast cancer patients: comparison to antigen quantification by ELISA.
Biermann JC; Holzscheiter L; Kotzsch M; Luther T; Kiechle-Bahat M; Sweep FC; Span PN; Schmitt M; Magdolen V
Int J Mol Med; 2008 Feb; 21(2):251-9. PubMed ID: 18204793
[TBL] [Abstract][Full Text] [Related]
22. Different prognostic value of cytokeratin-19 mRNA positive circulating tumor cells according to estrogen receptor and HER2 status in early-stage breast cancer.
Ignatiadis M; Xenidis N; Perraki M; Apostolaki S; Politaki E; Kafousi M; Stathopoulos EN; Stathopoulou A; Lianidou E; Chlouverakis G; Sotiriou C; Georgoulias V; Mavroudis D
J Clin Oncol; 2007 Nov; 25(33):5194-202. PubMed ID: 17954712
[TBL] [Abstract][Full Text] [Related]
23. E2F1 overexpression correlates with thymidylate synthase and survivin gene expressions and tumor proliferation in non small-cell lung cancer.
Huang CL; Liu D; Nakano J; Yokomise H; Ueno M; Kadota K; Wada H
Clin Cancer Res; 2007 Dec; 13(23):6938-46. PubMed ID: 18056168
[TBL] [Abstract][Full Text] [Related]
24. DNA methylation markers predict outcome in node-positive, estrogen receptor-positive breast cancer with adjuvant anthracycline-based chemotherapy.
Hartmann O; Spyratos F; Harbeck N; Dietrich D; Fassbender A; Schmitt M; Eppenberger-Castori S; Vuaroqueaux V; Lerebours F; Welzel K; Maier S; Plum A; Niemann S; Foekens JA; Lesche R; Martens JW
Clin Cancer Res; 2009 Jan; 15(1):315-23. PubMed ID: 19118060
[TBL] [Abstract][Full Text] [Related]
25. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion.
Hildenbrand R; Schaaf A
Int J Oncol; 2009 Jan; 34(1):15-23. PubMed ID: 19082473
[TBL] [Abstract][Full Text] [Related]
26. [mRNA expression of CK19 and CEA in peripheral blood of patients with breast cancer detected by real-time quantitative PCR].
Zheng HY; Chen Q; Ye YB; Huang WW
Zhonghua Yi Xue Za Zhi; 2008 Aug; 88(32):2267-70. PubMed ID: 19087676
[TBL] [Abstract][Full Text] [Related]
27. Multicenter study using paraffin-embedded tumor tissue testing PITX2 DNA methylation as a marker for outcome prediction in tamoxifen-treated, node-negative breast cancer patients.
Harbeck N; Nimmrich I; Hartmann A; Ross JS; Cufer T; Grützmann R; Kristiansen G; Paradiso A; Hartmann O; Margossian A; Martens J; Schwope I; Lukas A; Müller V; Milde-Langosch K; Nährig J; Foekens J; Maier S; Schmitt M; Lesche R
J Clin Oncol; 2008 Nov; 26(31):5036-42. PubMed ID: 18711169
[TBL] [Abstract][Full Text] [Related]
28. TSC22D1 and PSAP predict clinical outcome of tamoxifen treatment in patients with recurrent breast cancer.
Meijer D; Jansen MP; Look MP; Ruigrok-Ritstier K; van Staveren IL; Sieuwerts AM; van Agthoven T; Foekens JA; Dorssers LC; Berns EM
Breast Cancer Res Treat; 2009 Jan; 113(2):253-60. PubMed ID: 18299979
[TBL] [Abstract][Full Text] [Related]
29. Progesterone receptor B (PRB) promoter hypermethylation in sporadic breast cancer: progesterone receptor B hypermethylation in breast cancer.
Mc Cormack O; Chung WY; Fitzpatrick P; Cooke F; Flynn B; Harrison M; Fox E; Gallagher E; McGoldrick A; Dervan PA; McCann A; Kerin MJ
Breast Cancer Res Treat; 2008 Sep; 111(1):45-53. PubMed ID: 17896177
[TBL] [Abstract][Full Text] [Related]
30. GATA-3 expression in breast cancer has a strong association with estrogen receptor but lacks independent prognostic value.
Voduc D; Cheang M; Nielsen T
Cancer Epidemiol Biomarkers Prev; 2008 Feb; 17(2):365-73. PubMed ID: 18268121
[TBL] [Abstract][Full Text] [Related]
31. Cyclin A and E2F1 overexpression correlate with reduced disease-free survival in node-negative breast cancer patients.
Baldini E; Camerini A; Sgambato A; Prochilo T; Capodanno A; Pasqualetti F; Orlandini C; Resta L; Bevilacqua G; Collecchi P
Anticancer Res; 2006; 26(6B):4415-21. PubMed ID: 17201163
[TBL] [Abstract][Full Text] [Related]
32. Caspase 3 in breast cancer.
O'Donovan N; Crown J; Stunell H; Hill AD; McDermott E; O'Higgins N; Duffy MJ
Clin Cancer Res; 2003 Feb; 9(2):738-42. PubMed ID: 12576443
[TBL] [Abstract][Full Text] [Related]
33. High tumoral levels of Kiss1 and G-protein-coupled receptor 54 expression are correlated with poor prognosis of estrogen receptor-positive breast tumors.
Marot D; Bieche I; Aumas C; Esselin S; Bouquet C; Vacher S; Lazennec G; Perricaudet M; Kuttenn F; Lidereau R; de Roux N
Endocr Relat Cancer; 2007 Sep; 14(3):691-702. PubMed ID: 17914099
[TBL] [Abstract][Full Text] [Related]
34. FOXA1 expression in breast cancer--correlation with luminal subtype A and survival.
Badve S; Turbin D; Thorat MA; Morimiya A; Nielsen TO; Perou CM; Dunn S; Huntsman DG; Nakshatri H
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4415-21. PubMed ID: 17671124
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of estrogen receptor alpha and beta and progesterone receptor expression and correlation with clinicopathologic factors and proliferative marker Ki-67 in breast cancers.
Rosa FE; Caldeira JR; Felipes J; Bertonha FB; Quevedo FC; Domingues MA; Moraes Neto FA; Rogatto SR
Hum Pathol; 2008 May; 39(5):720-30. PubMed ID: 18234277
[TBL] [Abstract][Full Text] [Related]
36. Abnormal expression of 17beta-hydroxysteroid dehydrogenases in breast cancer predicts late recurrence.
Gunnarsson C; Olsson BM; Stål O;
Cancer Res; 2001 Dec; 61(23):8448-51. PubMed ID: 11731426
[TBL] [Abstract][Full Text] [Related]
37. In situ levels of oestrogen producing enzymes and its prognostic significance in postmenopausal breast cancer patients.
Licznerska BE; Wegman PP; Nordenskjöld B; Wingren S
Breast Cancer Res Treat; 2008 Nov; 112(1):15-23. PubMed ID: 18030614
[TBL] [Abstract][Full Text] [Related]
38. Survivin expression predicts early recurrence in early-stage breast cancer.
Yamashita S; Masuda Y; Kurizaki T; Haga Y; Murayama T; Ikei S; Kamei M; Takeno S; Kawahara K
Anticancer Res; 2007; 27(4C):2803-8. PubMed ID: 17695451
[TBL] [Abstract][Full Text] [Related]
39. Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group.
Kyndi M; Sørensen FB; Knudsen H; Overgaard M; Nielsen HM; Overgaard J;
J Clin Oncol; 2008 Mar; 26(9):1419-26. PubMed ID: 18285604
[TBL] [Abstract][Full Text] [Related]
40. Limits of predictive models using microarray data for breast cancer clinical treatment outcome.
Reid JF; Lusa L; De Cecco L; Coradini D; Veneroni S; Daidone MG; Gariboldi M; Pierotti MA
J Natl Cancer Inst; 2005 Jun; 97(12):927-30. PubMed ID: 15956654
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]